The effectiveness of alendronate (70 mg weekly) in women with postmenopausal osteoporosis

被引：0
|
作者：
Martchenkova, L. A. [1 ]
Dreval, A. V. [1 ]
Kryukova, I. V. [1 ]
Tishenina, R. S. [1 ]
Milov, N. M. [1 ]
机构：
[1] Moscow Reg Res Clin Inst, Moscow, Russia
来源：
OSTEOPOROSIS INTERNATIONAL | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [1] Preference study of alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis
    Palmisano, J
    Lewiecki, EM
    Rosen, C
    Bockman, RS
    Vanaman, LK
    Smith, ME
    Wang, L
    Thompson, D
    Yates, J
    [J]. OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S43 - S44
  • [2] Preference study of alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis
    Palmisano, J
    Melton, M
    Lewiecki, EM
    Rosen, R
    Bockman, RS
    Dinh, AC
    Smith, ME
    Wang, L
    Keene, W
    [J]. OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S36 - S36
  • [3] Preference study of alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis.
    Palmisano, J
    Lewiecki, EM
    Rosen, C
    Bockman, RS
    Vanaman, LK
    Smith, ME
    Wang, L
    Yates, J
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2002, 50 (04) : S64 - S64
  • [4] Alendronate 70 mg Once Weekly and alendronate 10 mg Once Daily preference study in postmenopausal women with osteoporosis.
    Palmisano, J
    Lewiecki, EM
    Rosen, C
    Bockman, RS
    Vanaman, LK
    Smith, M
    Wang, L
    Yates, J
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S404 - S404
  • [5] Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis
    Luckey, M
    Kagan, R
    Greenspan, S
    Bone, H
    Kiel, RDP
    Simon, J
    Sackarowitz, J
    Palmisano, J
    Chen, E
    Petruschke, RA
    de Papp, AE
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2004, 11 (04): : 405 - 415
  • [6] Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
    Casado, Enrique
    Rosas, Jose
    Rubio-Terres, Carlos
    Rubio-Rodriguez, Dario
    Boolell, Mitra
    Aristegui, Ignacio
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (11)
  • [7] Greater preference and better satisfaction with alendronate 70 mg weekly versus alendronate 10 daily for the treatment of postmenopausal osteoporosis
    Sawicki, Andrzej Z.
    [J]. MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2005, 4 (06): : 22 - 28
  • [8] Two year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis
    Rizzoli, R
    Roux, C
    Greenspan, S
    Bone, H
    Schnitzer, T
    Watts, N
    Adami, S
    Uebelhart, B
    Foldes, J
    Peverly, C
    Santora, A
    Kaur, A
    Wu, M
    Orloff, J
    [J]. JOURNAL OF RHEUMATOLOGY, 2001, 28 : 25 - 25
  • [9] Two year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis
    Rizzoli, R
    Roux, C
    Greenspan, S
    Bone, H
    Schnitzer, T
    Watts, N
    Adami, S
    Foldes, J
    Uebelhart, B
    Peverly, C
    Santora, A
    Kaur, A
    Wu, M
    Orloff, J
    [J]. BONE, 2001, 28 (05) : S94 - S94
  • [10] Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy
    M. Hiligsmann
    S. Maggi
    N. Veronese
    L. Sartori
    J.-Y. Reginster
    [J]. Osteoporosis International, 2021, 32 : 595 - 606
12345